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Abstract
This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics,
pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase
replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase
alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa
5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no
deaths/life-threatening serious adverse events (SAEs). One Naïve patient withdrew for study drug-related SAEs (respiratory distress/chest discomfort).
Infusion-associated reactions (IARs) affected 8 patients. Most treatment-emergent AEs/IARs were non-serious with mild-to-moderate intensity. At
screening, 5 Switch patients tested positive for anti-avalglucosidase alfa antibodies; on-treatment, 2 Switch and 9 Naïve patients seroconverted.
Post-infusion, avalglucosidase alfa plasma concentrations declined monoexponentially (t1/2z ∼1.0 h). AUC was 5–6 × higher in the 20 vs 5 mg/kg
group. Pharmacokinetics were similar between Switch and Naïve groups and over time. Baseline quadriceps muscle glycogen was low (∼6%)
in most patients, generally remaining unchanged thereafter. Exploratory efficacy parameters (pulmonary function/functional capacity) generally
remained stable or improved. Avalglucosidase alfa’s well-tolerated safety profile and exploratory efficacy results support further avalglucosidase alfa
development.
© 2018 The Authors. Published by Elsevier B.V.
Keywords: Alglucosidase alfa; Enzyme replacement therapy; Glycogen storage disease type II; Lysosomal acid α-glucosidase (GAA) deficiency;
Avalglucosidase alfa (neoGAA); Late-onset Pompe disease (LOPD).
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1. Introduction
Pompe disease, also known as glycogen storage disease
type II or acid maltase deficiency, is a progressive, rare
autosomal recessive disorder caused by mutations in the
gene that encodes acid α-glucosidase (GAA). Deficiency of
lysosomal GAA, an enzyme required for lysosomal glycogen
degradation, results in an accumulation of lysosomal and
eventually cytoplasmic glycogen [1–3]. Accumulation of
glycogen in the lysosome results in lysosomal swelling and
rupture [4]. Pompe disease exists as a spectrum of phenotypes,
and is often classified by age and symptoms at onset.
Classical infantile Pompe disease (IOPD) presents shortly
after birth and is characterized by prominent cardiomyopathy,
progressive generalized hypotonia, and rapid progression;
patients generally die within the first year when untreated.
When Pompe disease has a more gradual onset (late-onset
Pompe disease; LOPD), it presents as a proximal myopathy
with respiratory muscle involvement including the diaphragm,
but without cardiomyopathy. In these children and adults,
the disease course is more variable [5]. Onset of clinical
symptoms typically may occur from any time after the
first year of life to as late as the eighth decade [6,7]; a
small subset of patients present without cardiomyopathy at
<1 year of age [5,6]. The vast majority of patients present
during adulthood. Pompe disease incidence varies depending
on patients’ ethnicity, geographical region, and between the
different phenotypes [1].
Muscle pathology in LOPD is characterized by progressive
muscle damage starting with intralysosomal glycogen to
accumulation of storage material [8], autophagic build-up
[9], loss of contractile structure [10], muscle atrophy and
replacement by fat [11–13], and concomitant progressive loss
of function [14]. This process may already start in early life
[15] and clinically diagnosed symptomatic patients’ health
and functional status may already be severely impaired at
presentation [15–17]. For symptomatic patients with LOPD,
the risk of wheelchair use increases by 13% and the risk of
ventilator dependency increases by 8% for each additional
post-diagnosis year without treatment [18]. Patients requiring
both a wheelchair and respiratory support have higher
mortality than those requiring neither (5-year survival: 74%
vs 95%, respectively; p<0.002) [19].
Response to GAA replacement is determined by the
severity of damage at treatment initiation and extent of
lysosomal glycogen accumulation [15,20,21], and by the
magnitude of muscle GAA uptake achieved on therapy
[22,23]. Alglucosidase alfa is approved worldwide [24,25] for
Pompe disease treatment. Initial clinical trials in IOPD
patients demonstrated that alglucosidase alfa treatment
prolonged both overall and invasive ventilation-free survival,
as well as generally improved cardiomyopathy, motor
skills, and independent functional capacity [26,27]. The
Late-Onset Treatment Study (LOTS) [28,29], conducted in
children (aged ≥8 years) and adults with Pompe disease,
demonstrated that alglucosidase alfa stabilized respiratory
function and improved walking distance, and supported the

approval of alglucosidase alfa therapy for the whole spectrum
of Pompe disease.
Alglucosidase alfa clears glycogen storage in cardiac
muscle more effectively than in skeletal muscle [20,27],
which may, in part, reflect tissue differences in cationindependent mannose 6-phosphate (CIM6P)/insulin growth
factor II (IGFII) receptor expression and enzyme uptake
[26–32]. Also, most LOPD patients, who typically have
more residual GAA activity than patients with the infantile
form, are generally spared cardiac involvement, indicating
that cardiac muscle is likely to require less GAA activity
to prevent and remediate glycogen storage [2]. The cellsurface CIM6P/IGFII receptor mediates cellular uptake
of exogenous GAA and targets it to the lysosomal
compartment [33]. Thus, M6P levels and exposure enable
enzyme uptake and internalization, and increasing M6P on
the recombinant enzyme may increase achieved skeletal
muscle uptake [34]. Avalglucosidase alfa (neoGAA) is
a second-generation, glycoengineered recombinant GAA
replacement therapy with increased bis-M6P levels on the
molecule in order to increase receptor-mediated uptake
(Fig. 1).
Preclinical studies in a Pompe disease mouse model have
shown that compared with alglucosidase alfa, avalglucosidase
alfa has a 1000-fold higher binding affinity to M6P receptors
[22,23] and greater glycogen clearance from muscle on
a mg alglucosidase alfa/mg avalglucosidase alfa basis,
i.e., equivalent clearance to rhGAA at one-fifth the dose
[22]. In GAA knockout mice, 4 mg/kg is the minimum
pharmacologically active dose for cardiac and 12 mg/kg for
skeletal muscle [35]. The first dose of avalglucosidase alfa
administered to patients in our study was 5 mg/kg actual
body weight, which was cumulatively based upon nonclinical
safety information, the maximum recommended starting
dose per the Food and Drug Administration guidance [36],
International Conference on Harmonization M3 guidance
[37], and the observed potency and pharmacologically active
dose of avalglucosidase alfa in all target tissues from
multiple nonclinical studies in mice. Avalglucosidase alfa
doses were planned to be administered in an ascending
manner, and for each dose escalation the increment was 2fold, and was supported by the monitoring of potential safety
signals. This escalation strategy took into consideration the
pharmacologically active dose of 12 mg/kg in skeletal muscle
from preclinical studies [35].
The objectives of this open-label, ascending-dose study
(NEO1; ClinicalTrials.gov identifier: NCT01898364) were
to evaluate the safety and tolerability of avalglucosidase
alfa, characterize its pharmacodynamic and pharmacokinetic
profiles, and assess exploratory efficacy endpoints following
repeated dose administrations in adults with Pompe disease,
who were either alglucosidase alfa-naïve (Naïve Group)
or had received alglucosidase alfa for ≥9 months (Switch
Group). We emphasize that this study was, by design, a
phase 1 study focusing on safety and enrolling a small
patient cohort; for this reason the efficacy assessments were
designated by protocol as exploratory.
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Fig. 1. Structures of (a) Alglucosidase alfa and (b) Investigational avalglucosidase alfa second-generation acid α-glucosidase replacement therapy. Increased
bis-mannose 6-phosphate (M6P) levels on avalglucosidase alfa favor uptake by cation-independent M6P receptors. Fig. 1b Reprinted (adapted) with permission
from Zhou Q, et al. Bioconjugate Chem 2011;22:741–751. Copyright 2011 American Chemical Society.

2. Patients and methods
2.1. Participants and study design
This was a multicenter, multinational, open-label,
ascending dose study, with every-other-week intravenous
(IV) infusions of avalglucosidase alfa; the study design is
presented in Fig. 2.
Eligible patients were male or female, aged ≥18 years,
with confirmed GAA enzyme deficiency from any tissue
source and/or two confirmed pathogenic GAA gene variants,
and without known cardiac hypertrophy. Samples for GAA
genotyping were taken at baseline, if historical samples
were not available. Patients had to be able to walk 50 m
without stopping or using an assistive device and had to have
an upright forced vital capacity (FVC) of ≥50% predicted
according to Hankinson et al. [38]. Fertile women had to
test negative for pregnancy at baseline and, if sexually active,
use two acceptably effective contraception methods during
treatment.
Patients were excluded if they were wheelchair-dependent,
required invasive ventilation, were participating in another
clinical study using investigational treatments, or were,
in the opinion of the investigator, unable to adhere to
study requirements. Patients were also excluded if they

had clinically significant organic disease (apart from Pompe
disease symptoms), e.g., cardiovascular, hepatic, pulmonary,
neurologic, or renal disease, or had other medical conditions,
serious intercurrent illness, or extenuating circumstance that,
in the opinion of the investigator, precluded participation in
the study or potentially decreased survival. Patients with MRI
contraindications were also excluded. Conditions suggesting
high risk for allergy to avalglucosidase alfa, e.g., previous
moderate-to-severe anaphylactic reaction to alglucosidase
alfa, immunoglobulin (Ig) E antibodies, and/or a history of
sustained high IgG antibody titers to alglucosidase alfa, were
exclusionary.
Patients were screened within 90 days before study
inclusion and treatment initiation. For the Naïve Group,
skeletal muscle MRI and biopsy and all baseline efficacy
assessments were performed ≤21 days before avalglucosidase
alfa initiation, and for the Switch Group, these were
performed after the last alglucosidase alfa administration and
≤21 days before avalglucosidase alfa initiation.
Eligible patients, either naïve to alglucosidase alfa therapy
(Naïve Group) or previously treated with alglucosidase alfa
for ≥9 months (Switch Group), received every-other-week
avalglucosidase alfa IV infusions at 5, 10, or 20 mg/kg actual
body weight, totaling 13 infusions over 24 weeks. Each
infusion was administered stepwise, beginning at a slow

170

L.D.M. Pena, R.J. Barohn and B.J. Byrne et al. / Neuromuscular Disorders 29 (2019) 167–186

Fig. 2. Study design.
∗ For the Naïve Group, skeletal muscle MRI and biopsy and all efficacy assessments were performed within 21 days before avalglucosidase alfa initiation; for
the Switch Group, these were performed after the last alglucosidase alfa administration and ≤21 days before avalglucosidase alfa treatment.
Exploratory efficacy assessments included: pulmonary function testing; 6-min walk test; Gait, Stair, Gowers’ maneuver, Chair test; Gross Motor Function
Measure-88; Quick Motor Function Test; hand-held dynamometry test; and Pediatric Quality of life Inventory Multidimensional Fatigue Scale – Adult Report.
W, Week; D, avalglucosidase alfa infusion; PTE, post-treatment evaluation; EOS, end of study visit; SR, safety review by Data Monitoring Committee.

initial rate and gradually increasing if there were no signs
of infusion-associated reactions (IARs), up to a maximum
of approximately 7 mL/kg/h; total infusion time depended on
dose. For management of mild IARs, infusion rate reductions
or temporary interruptions were allowed. For moderate-tosevere or recurrent IARs, the investigator could consider using
pre-treatment medications (i.e., antihistamines, antipyretics,
and/or glucocorticoids), in addition to infusion rate reductions,
interruptions, or discontinuation, if necessary.
Study duration for each patient was approximately
41 weeks from screening to study end. This included:
screening within 90 days before inclusion and treatment
initiation, a baseline evaluation, a 24-week treatment period
(Weeks 1–25), a post-treatment evaluation 2 weeks after the
last infusion (Week 27), and an end-of-study visit 4 weeks
after the final infusion (Week 29).
The study protocol was approved by Independent Ethics
Committees/Institutional Review Boards at participating
centers (Supplementary Table S1). All patients provided
written informed consent.
2.2. Safety
Patients were continuously monitored throughout the
study for safety, including IARs, via patient-reported and/or
investigator-observed adverse events (AEs). Standard clinical
laboratory evaluations (biochemistry, hematology, urinalysis,
and vital signs) were assessed at screening/baseline and
at each biweekly clinic visit from Week 1 through
Week 25. Patients had a physical examination, 12lead electrocardiogram (ECG), and were weighed at
screening/baseline; physical examinations were also made at

Weeks 13 and 25, and ECG and body weight measurements
at Weeks 1, 13, and 25. Blood samples to test for
anti-avalglucosidase alfa antibodies, and for neutralizing
antibodies in anti-avalglucosidase alfa antibodies-positive
patients, were collected at baseline (within 24 h before the
first infusion) and at Weeks 1, 5, 9, 13, 17, 21, 25, and
27. In addition, for Switch Group patients, samples at
Weeks 1 and 25 were analyzed for anti-alglucosidase alfa
antibodies. IgE, complement, serum tryptase, and circulating
immune complexes were tested only in patients with potential
hypersensitivity IARs.
2.3. Pharmacokinetics
Blood samples for pharmacokinetic analysis were collected
at Weeks 1 (Day 1), 13, and 25, prior to avalglucosidase
alfa infusion, immediately before the infusion rate changed
from 1 to 3 mg/kg/h, from 3 to 5 mg/kg/h, and from 5
to 7 mg/kg/h, immediately before the end of infusion (0 h),
and at 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 h
after the end of infusion. Avalglucosidase alfa activity was
determined using a qualified, sensitive fluorometric assay,
with 4-methylumbelliferyl-α-D-glucoside pyranoside as the
substrate; the lower limit of quantification was 13 ng/mL.
The following pharmacokinetic parameters were calculated
for plasma concentrations of avalglucosidase alfa after
single and multiple doses using non-compartmental methods:
maximum plasma concentration observed (Cmax ); time to
reach Cmax (tmax ); area under the plasma concentration–time
curve (AUC) calculated using the trapezoidal method from
time zero to the real-time tlast (AUClast ); AUC extrapolated
to infinity (AUC∞ ); terminal half-life (t1/2z ; i.e., the terminal
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half-life associated with the terminal slope [λz ]); apparent
total body clearance from plasma (CL); and volume of
distribution at steady-state (Vss ).
2.4. Pharmacodynamics
The following pharmacodynamic parameters were
assessed after single and multiple dose administration of
avalglucosidase alfa: skeletal muscle glycogen content by
MRI; qualitative (T1 -weighted Mercuri scoring; 1: normal,
2: <30% fat, 3: ≥30% to <60% fat, and 4: ≥60% fat)
and quantitative (3-point Dixon, T2 ); fasted urinary glucose
tetrasaccharide (Hex4 ); and exploratory fasted plasma and
urine biomarkers.
MRI and skeletal muscle biopsies were performed
at baseline (within 21 days before treatment start) and
post-treatment (Week 27). Normal-appearing muscle tissue
(determined by MRI guidance) was sampled to prevent
biopsy of fatty or fibrotic tissue. Glycogen content was
measured in skeletal muscle biopsies by computer-assisted
histomorphometric analysis (MetaMorph® ) of high-resolution
light microscopy sections as previously described [20,39].
Briefly, to quantify accurately the distribution of glycogen
across the entire specimen, up to 10 epoxy resin blocks were
processed per sample-time point for each patient. One slide
from each block was analyzed; values obtained were averaged
to obtain a mean ± standard deviation (SD) for each patienttime point. Data were expressed as the % tissue area occupied
by glycogen.
Fasted urine Hex4 and exploratory urine biomarker samples
were collected at baseline, and every other week during
treatment, and the exploratory plasma samples were collected
at baseline, and Weeks 1, 3, 5, 9, 13, 17, 21, and 25;
all samples were taken within 24 h before avalglucosidase
alfa infusion. The exploratory urine and plasma biomarker
analyses are pending and will be reported separately in the
future.
2.5. Exploratory efficacy
Avalglucosidase alfa efficacy on functional capacity and
strength was evaluated using several functional outcome
measures. Exploratory assessments were made at baseline and
at Weeks 13 and 25 within 24 h before avalglucosidase alfa
infusion; changes from baseline to Weeks 13 and 25 were
calculated.
Pulmonary function testing followed American Thoracic
Society guidelines [40] and included the assessment of FVC,
forced expiratory volume in 1 s (FEV1 ), maximal inspiratory
pressure (MIP), maximal expiratory pressure (MEP), and peak
expiratory flow (PEF) in the upright and supine positions
(only upright data are reported). The % of predicted normal
values for MIP and MEP were calculated according to
Evans and Whitelaw [41] and for the FVC, FEV1 , and PEF
according to Hankinson et al. [38].
The 6-min walk test (6MWT) was conducted according
to American Thoracic Society guidelines [42]. Changes in
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meters walked from baseline and changes in % predicted from
baseline were calculated at each assessment point. Predicted
values were calculated according to Enright and Sherrill [43].
The Gait, Stair, Gowers’ Maneuver, Chair (GSGC) test
[44] consists of four functional tests (gait, climbing stairs,
Gowers’ maneuver, and arising from a chair). Each test
is scored from 1 (normal function) to 7 (poor function)
and the total score calculated by summing the four test
scores. Missing tasks were imputed as if subjects could
not perform them. Gross Motor Function Measure-88
(GMFM-88) assessment was developed specifically to detect
quantitative changes in gross motor function [45]. Of the
five dimensions to the GMFM-88, two were evaluated in this
study: Dimensions D (standing) and E (walking, running, and
jumping; GMFM-88-DE). The Quick Motor Function Test
(QMFT) [46], is an observer-administered test comprising 16
items specifically difficult for Pompe disease patients. Items
are scored individually on a 5-point ordinal scale (0–4), with
a total for all items of 0–64 points; lower scores indicate
worse motor function. For the hand-held dynamometry (HHD)
test, the examiner held the dynamometer stationary while
the patient exerted a maximal force against it, making
a gradual increase in force and then completing a 4–5 s
isometric hold. Limb tests (shoulder, elbow, hip, knee, and
ankle) and grip strength were completed bilaterally because
dominant and non-dominant limbs may differ. Each muscle
group was measured twice and the highest score analyzed.
Individual test scores were summed for the upper and lower
body.
The 18-item Pediatric Quality of Life Inventory
Multidimensional Fatigue Scale – Adult Report, Standard
Version (PedsQLTM ) [47] encompasses three subscales:
General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue.
Six general fatigue items measure lack of strength and
endurance to complete activities of daily living, six sleep/rest
fatigue items measure sleep problems and number of
naps/day, and six cognitive fatigue items measure the impact
of fatigue on attention and memory. Items are evaluated on a
5-point Likert scale, reverse-scored, and linearly transformed
to a 1–100 scale. A total score was calculated as the mean
derived from the sum of the transformed items divided by
the number of items answered on the scales. Higher scores
denote better health-related quality of life.
2.6. Statistical methods
In total, 21 patients were planned empirically to complete
the study; no formal sample size calculations were performed.
The full analysis set (all patients who received ≥1 complete
infusion of avalglucosidase alfa), the safety analysis set (all
patients who received any amount of avalglucosidase alfa)
and the pharmacokinetic analysis set (patients without any
major deviations related to study drug administration who
had available pharmacokinetic data) comprised the same
patients. Demographic and baseline data for medical/surgical
history and Pompe disease history were summarized using
summary statistics for continuous variables and frequency
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Enrolled: 24 patients

Naïve Group
(naïve to alglucosidase alfa
therapy):
10 patients

5 mg/kg
avalglucosidase
alfa:
4 patients

10 mg/kg
avalglucosidase
alfa:
3 patients

Switch Group
(prior alglucosidase alfa
therapy for ≥9 months):
14 patients

20 mg/kg
avalglucosidase
alfa:
3 patients

1 patient
discontinued
due to SAE

Completed:
3 patients

5 mg/kg
avalglucosidase
alfa:
4 patients

10 mg/kg
avalglucosidase
alfa:
4 patients

20 mg/kg
avalglucosidase
alfa:
6 patients

1 patient
withdrew
consent

Completed:
3 patients

Completed:
3 patients

Completed:
3 patients

1 patient
withdrew
consent

Completed:
4 patients

Completed:
5 patients

SAE, serious adverse event
Fig. 3. Flow diagram for disposition of patients during the study.

distribution for categorical variables. Safety evaluation was
based on a review of descriptive statistics and individual
data for AEs, immunogenicity, clinical laboratory, vital
sign, and ECG parameters. Exploratory functional efficacy
variables measured at baseline, Week 13, and Week 25
were summarized using summary statistics. Non-parametric
methods were used as part of a sensitivity analysis. We
found the results robust, but choose to provide the parametric
method as it better models the data.

n=3; 20 mg/kg, n=3) and 14 patients in the Switch Group
(5 mg/kg, n=4; 10 mg/kg, n=4; 20 mg/kg, n=6). In the Naïve
Group, 1 patient in the 5 mg/kg group discontinued treatment
due to serious AEs (SAEs) of respiratory distress and chest
discomfort; these occurred during the ninth avalglucosidase
alfa infusion and were considered IARs. In the Switch
Group, 2 patients discontinued treatment for non-AE-related
reasons (1 patient in the 5 mg/kg group following the last
avalglucosidase alfa infusion and 1 patient in the 20 mg/kg
group following their eighth avalglucosidase alfa infusion).

3. Results
3.1. Study sites

3.3. Demographics and Pompe disease history

The study was carried out at 17 centers (seven in the
United States, three in France, three in Germany, and at
one center each in Belgium, Denmark, Netherlands, and the
United Kingdom). Study sites and NEO1 investigators are
listed in Supplementary Table S2.

Patient demographics and Pompe disease history for the
overall Naïve and Switch Groups are presented in Table 1
and by treatment groups in Supplementary Table S3. Overall,
in the Naïve and Switch Groups, 30% (3/10) and 64% (9/14),
respectively, of patients were male, and most were Caucasian
(88% [21/24]). A confirmed Pompe disease family history
was recorded in 42% (10/24) of patients and 38% (9/24) had
an affected sibling.
Mean±SD age of patients at Pompe disease diagnosis was
43.3±23.8 years for the Naïve Group and 36.3±16.4 years for
the Switch Group. Median ages of patients at Pompe disease
diagnosis were similar for the two groups (Naïve Group: 36.4

3.2. Patient disposition
The first patient was enrolled into the study on August
19, 2013 and the last completed the study on February 25,
2015. In total, 24 patients were enrolled and treated (Fig.
3); 10 patients in the Naïve Group (5 mg/kg, n=4; 10 mg/kg,
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Table 1
Demographic characteristics and Pompe disease history.
Parameter

Naïve Group (alglucosidase alfa
treatment-naïve Pompe disease
patients; n=10)

Age at study enrollment, years, mean ± SD
Sex, female/male, n (%)
Race, n (%)
Black or African American
White
Multiple
Other
Hispanic/non-Hispanic, n (%)
Height, cm, mean ± SD
Weight, kg, mean ± SD
Body mass index, kg/m2 , mean ± SD (median [range])

44.8 ± 20.26
7 (70)/3 (30)

46.7 ± 14.11
5 (36)/9 (64)

0 (0)
8 (80)
1 (10)
1 (10)
0 (0)/10 (100)
170.8 ± 8.20
65.0 ± 9.85
22.3 ± 3.14
(23.2 [17.0−26.1])
43.3 ± 23.79∗
(36.4 [15.8, 78.2])
4 (40)/6 (60)
3 (30)/1 (10)

1 (7)
13 (93)
0 (0)
0 (0)
0 (0)/14 (100)
176.3 ± 10.82
76.7 ± 15.84
24.6 ± 3.69
(24.1 [17.0−31.0])
36.3 ± 16.39†
(34.2 [3.4, 62.9])
6 (43)/8 (57)
6 (43)/0 (0)

8
1
0
1

11 (79)
1 (7)
2 (14)
0 (0)

Age at Pompe disease diagnosis, years, mean ± SD (median [range])
Pompe disease family history, yes/no, n (%)
If yes, relationship to patient, siblings/cousins, n (%)
Assistive walking devices and orthoses, n (%)
None
Rolling walker
Straight cane
Other: two walking sticks (poles)

(80)
(10)
(0)
(10)

Switch Group (Pompe disease patients
previously treated with alglucosidase
alfa for ≥9 months; n=14)

SD, standard deviation.
∗ n=8.
† n=9.

[range 15.8, 78.2] years; Switch Group: 34.2 [range 3.4, 62.9]
years). Patients entered the current study at various times
after initial diagnosis (mean age at study enrollment was
44.8±20.3 years for the Naïve Group and 46.7±14.1 years for
the Switch Group). In the Switch Group, 9 patients had full
data for pre-study alglucosidase alfa treatment duration, which
ranged from 0.9 to 7.9 years. Overall, 21% (5/24) of patients
used a walking device at baseline (Naïve Group: 20%; Switch
Group: 21%).
During the study, 7 patient samples were genotyped
for pathogenic GAA variants and the remaining genotypes
were retrieved from historic patient data. All genotypes
were consistent with an LOPD diagnosis. Eighteen patients
had the common c.-32-13T>G splice variant in compound
heterozygosity with another GAA pathogenic variant. Six
patients had two pathogenic GAA variants not including c.32-13T>G.
3.4. Safety
3.4.1. Adverse events
In both groups, avalglucosidase alfa was generally welltolerated at all doses; no deaths or life-threatening SAEs
were reported. Most treatment-emergent AEs (TEAEs) were
non-serious, with mild-to-moderate intensity (95% [169/176]).
Regardless of relationship to treatment, overall, 80% (8/10)
of Naïve Group patients and 86% (12/14) of Switch Group
patients experienced ≥1 TEAE, with respective group totals
of 83 and 93 TEAEs. TEAEs considered related to the study
drug (Table 2); occurred in 60% (6/10) of Naïve Group

patients (16 events), and in 50% (7/14) of Switch Group
patients (26 events). The number of patients experiencing ≥1
TEAE and the number of events during the study were similar
across all doses and for each group.
In the Naïve Group, across all doses, common TEAEs
regardless of their relationship to study drug included
headache (8 events in 4 patients), rash (8 events in 3 patients),
dizziness (7 events in 3 patients), nausea (4 events in 3
patients), oral herpes (4 events in 1 patient), dysmenorrhea
(4 events in 2 patients), and diarrhea (3 events in 3
patients). In the Switch Group, across all doses, common
TEAEs regardless of their relationship to study drug included
headache (10 events in 3 patients), myalgia (6 events in 1
patient), musculoskeletal pain (4 events in 3 patients), falls
(4 events in 2 patients), and nasopharyngitis (3 events in 3
patients).
In the Naïve Group, there were two study drug-related
SAEs (respiratory distress and chest discomfort) reported by
1 patient in the 5 mg/kg group at the ninth infusion (Week
17); both were study drug-related IARs and led to treatment
discontinuation and study withdrawal. The TEAE of chest
discomfort was considered to be severe and began 3 min
into infusion along with a cough (moderate). Three minutes
later the TEAE of respiratory distress began and flushing
1 min later; both were considered moderate in intensity.
All TEAEs resolved, with the flushing and chest discomfort
resolving approximately 7–9h after onset, the TEAE of
cough resolving approximately 1.5 days later, and respiratory
distress resolving 3 days later. In addition, the patient
reported dizziness and nausea, which occurred following
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Table 2
Number (%) of patients with study drug-related treatment-emergent adverse events by Medical Dictionary for Regulatory Activities (MedDRA) preferred
term.
MedDRA: Preferred term

Any events
Fatigue
Nausea
Abdominal pain
Asthenia
Balanoposthitis
Chest discomfort
Cough
Diarrhea
Dizziness
Dyspnea
Erythema
Facial pain
Flushing
Gastroesophageal reflux disease
Headache
Hypersensitivity
Hypotension
Infusion site reaction
Muscle spasms
Myalgia
Pruritus
Pulmonary function test decreased
Rash
Respiratory distress
Somnolence

Naïve Group (alglucosidase alfa
treatment-naïve Pompe disease
patients; n=10)
Patients, n (%)
6 (60)
2 (20)
2 (20)
0 (0)
0 (0)
0 (0)
1 (10)
1 (10)
0 (0)
1 (10)
1 (10)
1 (10)
0 (0)
1 (10)
1 (10)
1 (10)
0 (0)
0 (0)
0 (0)
0 (0)
1 (10)
0 (0)
0 (0)
1 (10)
1 (10)
0 (0)

treatment with 50 mg IV diphenhydramine hydrochloride.
The patient received epinephrine during the IAR and had
not received pre-infusion antipyretics, antihistamines, or
steroids.
In the Switch Group, 1 patient in the 5 mg/kg group
experienced one treatment-emergent SAE (gastrointestinal
hemorrhage), which did not lead to treatment discontinuation
or study withdrawal, and was not considered study drugrelated.
For both groups, the majority of TEAEs were mild across
all dose levels. Fifteen of the 24 enrolled patients reported
having used concomitant medications during the study for
TEAEs.
3.4.2. Infusion-associated reactions
Overall, 25 IARs were reported/identified in 8 patients
across both groups.
In the Naïve Group, 40% (4/10) of patients reported a total
of 11 IARs; the most commonly reported (2/11 IARs) was
flushing; all other IARs occurred once. All IARs were nonserious except for the two IARs in the patient at 5 mg/kg that
led to study withdrawal as described in Section 3.4.1. This
patient experienced six IARs (chest discomfort [SAE], cough,
respiratory distress [SAE], flushing, dizziness, and nausea) at
the ninth avalglucosidase alfa infusion (Week 17). The patient
had also experienced IARs of rash following the second
infusion and flushing following the eighth infusion; at the

Switch Group (Pompe disease patients
previously treated with alglucosidase
alfa for ≥9 months; n=14)
Patients, n (%)
7 (50)
1 (7)
0 (0)
1 (7)
1 (7)
1 (7)
0 (0)
0 (0)
1 (7)
1 (7)
1 (7)
0 (0)
1 (7)
0 (0)
0 (0)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
0 (0)
1 (7)

time both were considered possibly study drug-related. This
patient was negative for anti-avalglucosidase alfa antibodies
at screening and seroconverted at Week 13 with a titer of
1600; immediately before the ninth infusion the titer was
3200. Further samples collected following the ninth infusion
were negative for anti-avalglucosidase alfa IgE antibodies,
positive for complement activation, and tryptase (3.6 μg/L)
was within the normal range (i.e., ≤12.5 μg/L). None of the
anti-avalglucosidase alfa antibodies inhibited enzyme uptake
or enzymatic activity.
One Naïve Group patient at 20 mg/kg experienced an IAR
of erythema following the fourth infusion. The patient was
negative for anti-avalglucosidase alfa antibodies at screening
and seroconverted at Week 9, with sustained antibody titers
ranging from 400 to 800 until study end. Samples collected
following this event were negative for anti-avalglucosidase
alfa IgE antibodies and complement activation, and tryptase
(2.4 μg/L) was within the normal range. None of the antiavalglucosidase alfa antibodies inhibited enzyme uptake or
enzymatic activity.
In the Switch Group, 29% (4/14) of patients reported 14
IARs; all were non-serious. The most common IARs were
myalgia (6 events in 1 patient) and headache (2 events in
1 patient), with all other IARs occurring only once. Three
IARs (hypersensitivity, pruritus, and generalized rash) were
reported by 1 Switch Group patient at 20 mg/kg during the
thirteenth avalglucosidase alfa infusion. Samples collected
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in association with these IARs were negative for antiavalglucosidase alfa IgE antibodies, positive for complement
activation, and tryptase (4.7 μg/L) was within the normal
range.
3.4.3. ECG assessments and clinically relevant laboratory
abnormalities
There were no individual clinically relevant abnormalities
in ECG data for any patients. In the Switch Group, 2
patients had clinically relevant laboratory abnormalities. One
patient (10 mg/kg group) had hypokalemia in Week 15,
which was considered a mild TEAE, unlikely related to
avalglucosidase alfa, and was resolved by Week 17, with no
requirement for concomitant medication. The other patient
(5 mg/kg group) had severe TEAEs of hypovolemia and
anemia, which began on Day 48, 3 days following the fourth
infusion; this is the same patient who experienced a SAE of
a gastrointestinal bleed on Day 48 (as mentioned in Section
3.4.1.) Neither the gastrointestinal bleed nor the associated
TEAEs were considered related to avalglucosidase alfa. The
hypovolemia and anemia resolved after approximately 3 and
5 months, respectively; both were treated with concomitant
medications.
3.4.4. Immunogenicity
In the Naïve Group, 90% (9/10) of patients developed
antibodies to avalglucosidase alfa during treatment, with a
median peak titer of 1600 (range 200–25,600) observed across
all treatments. Mean time to seroconversion from first infusion
was 56.9±14.9 (median 56 [range 28–87]) days, with the
peak titer occurring on average 108.4±37.7 (median 89 [range
77–175]) days from first infusion. After seroconversion, 1
patient had sustained and elevated titers (defined by protocol
as a peak titer ≥25,600, and a last titer that was equal to,
higher than, or one 2-fold dilution level lower than the peak
titer); this patient’s peak titer was 25,600. This patient showed
improvement on pulmonary and motor function testing. Two
patients who had seroconverted had decreased titers later (i.e.,
at least 4-fold lower than the peak titer); 1 of these patients
decreased by 8-fold (three dilution levels), and the other
patient was negative for antibodies at the final time point after
a peak titer of 1600, suggesting that this patient may have
tolerized. One patient (5 mg/kg) tested positive for uptakeinhibitory antibodies at Week 27; no anti-avalglucosidase
alfa antibodies inhibited enzymatic activity. As noted in
Section 3.4.2., 2 Naïve Group patients tested negative for antiavalglucosidase alfa IgE.
In the Switch Group, 36% (5/14) of patients tested
positive for antibodies to avalglucosidase alfa at screening,
with a maximum titer of 1600 observed at Week 1. Titers
in 2 of the 5 patients demonstrated a treatment-boosted
response with 4- and 8-fold increased titers from the
baseline levels, with a maximum titer of 12,800. Of the
9 patients who tested negative at screening and Week 1
for anti-avalglucosidase alfa antibodies, 2 (22%) patients
seroconverted after Week 1, with a maximum titer of 1600.
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Overall mean time to avalglucosidase alfa seroconversion was
4.7±46.6 (median –12.0 [range –44.0 to 84.0]) days from
first on-study infusion (Week 1). Peak titers for patients
who seroconverted or exhibited a boosted response (n=4)
occurred on average 143±27.0 (median 142 [range 111–175])
days after first infusion. For the 5 patients with pre-study
positive antibodies and 2 patients who seroconverted during
the study, the median peak titer was 400 (range 200–12,800).
No patient had sustained and elevated titers, and 2 patients
(14.3%) had decreased titers (which may be within-assay
variability, as none decreased >2-fold). None of the antiavalglucosidase alfa antibodies inhibited enzyme uptake or
enzymatic activity. At Week 1, 50% (7/14) of Switch Group
patients tested positive for IgG antibodies to alglucosidase
alfa, with a maximum titer of 6400. Of the 7 Switch Group
patients who tested negative at Week 1 for anti-alglucosidase
alfa antibodies, 3 patients seroconverted with antibodies to
alglucosidase alfa during avalglucosidase alfa treatment, with
a maximum observed titer of 3200 (range 1600–3200). As
noted in Section 3.4.2., 1 patient in the Switch Group tested
negative for anti-avalglucosidase alfa IgE.
3.5. Pharmacokinetics
Pharmacokinetics for the Naïve and Switch Groups are
presented in Tables 3 and 4, respectively. In both the
Naïve and Switch Groups, avalglucosidase alfa exposure
increased with dose (in the 20 mg/kg group the AUC was
approximately 5–6 × greater than in the 5 mg/kg); mean
systemic CL ranged from 0.92 to 1.28 L/h and 1.0 to 1.57 L/h,
respectively, and mean Vss ranged from 2.40 to 3.02 L and
2.83 to 3.71 L, respectively. Within each treatment group,
the pharmacokinetic parameters appeared similar at Weeks
1, 13, and 25, indicating no apparent effect of every-otherweek dosing on avalglucosidase alfa pharmacokinetics. The
pharmacokinetic parameters also appeared generally similar
between the Naïve and Switch groups.
The mean avalglucosidase alfa plasma concentration–
time profiles are presented in Fig. 4A–C. In both groups,
avalglucosidase alfa plasma concentrations appeared to
decline monoexponentially from 8 to 12 h after the end
of the infusion; mean t½z ∼1.0 h for each group (range
0.66–1.53 h). However, consistent avalglucosidase alfa plasma
concentrations of approximately 20 ng/mL were observed
from approximately 12 h post infusion to the last sample
taken, likely representing the endogenous enzyme levels. For
both groups, the accumulation ratios at Weeks 13 and 25,
based on AUC values, were generally close to 1.0, which
was consistent with the short t½z and every-other-week dosing
regimen.
3.6. Pharmacodynamics
Quadriceps biopsies were available at baseline and Week
27 for 9 patients who completed the study in each of
the Naïve and Switch groups. Mean±SD quadriceps muscle
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Table 3
Avalglucosidase alfa pharmacokinetic parameters for alglucosidase alfa treatment-naïve Pompe disease patients (Naïve Group).
Parameter

Cmax , ng/mL, mean ± SD
(geometric mean) [CV%]

Week∗

1
13
25

tmax , h, median (min−max)
AUClast , ng·h/mL, mean ± SD
(geometric mean) [CV%]

1
13
25
1
13
25

AUC, ng·h/mL, mean ± SD
(geometric mean) [CV%]

1
13
25

t½z , h, mean ± SD
(geometric mean) [CV%]

1
13
25

CL, mL/h, mean ± SD
(geometric mean) [CV%]

1
13
25

Vss , mL, mean ± SD
(geometric mean) [CV%]

1
13
25

tlast , h, median (min−max)
Clast , ng/mL, mean ± SD
(geometric mean) [CV%]

1
13
25
1
13
25

Accumulation ratio (AUC)

13
25

Avalglucosidase alfa
5 mg/kg (n=4, Week 1;
n=3 Weeks 13 and 25)

10 mg/kg (n=3)

82,300 ± 6690
(82,100) [8.1]
98,700 ± 38,900
(93,700) [39.4]
89,100 ± 11,000
(88,600) [12.3]
1.71 (1.47−2.58)
1.60 (1.50−1.80)
1.43 (1.43−1.62)
259,000 ± 37,600
(259,000) [14.5]
285,000 ± 82,900
(276,000) [29.1]
264,000 ± 50,200
(261,000) [19.0]
259,000 ± 37,600
(257,000) [14.5]
285,000 ± 82,900
(276,000) [29.1]
264,000 ± 50,200
(261,000) [19.0]
0.784 ± 0.369
(0.727) [47.1]
1.34 ± 1.05
(1.10) [78.2]
0.777 ± 0.0455
(0.776) [5.9]
1260 ± 203
(1240) [16.2]
1220 ± 307
(1190) [25.2]
1230 ± 229
(1220) [18.5]
2620 ± 396
(2600) [15.1]
2650 ± 803
(2540) [30.3]
2400 ± 316
(2390) [13.1]
9.63 (9.57−17.77)
14.69 (9.83−33.50)
12.53 (9.62−13.82)
65.8 ± 102
(29.2) [154.4]
18.5 ± 7.14
(17.6) [38.6]
64.3 ± 72.5
(42.1) [112.7]
1.10
1.02

190,000 ± 40,100
(187,000) [21.1]
151,000 ± 29,700
(149,000) [19.7]
162,000 ± 26,500
(161,000) [16.4]
2.30 (2.23−2.30)
2.33 (1.48−2.35)
2.35 (2.35−2.45)
529,000 ± 79,600
(525,000) [15.0]
529,000 ± 41,800
(528,000) [7.9]
565,000 ± 89,800
(560,000) [15.9]
529,000 ± 79,600
(525,000) [15.0]
529,000 ± 41,900
(528,000) [7.9]
565,000 ± 89,800
(560,000) [15.9]
0.833 ± 0.493
(0.750) [59.2]
0.738 ± 0.133
(0.730) [18.1]
0.856 ± 0.235
(0.835) [27.5]
1240 ± 386
(1190) [31.3]
1280 ± 261
(1270) [20.3]
1180 ± 176
(1170) [14.9]
2480 ± 626
(2420) [25.3]
3020 ± 766
(2960) [25.4]
2670 ± 109
(2670) [4.1]
12.47 (12.43−12.47)
14.33 (12.67−15.28)
14.10 (12.60−18.47)
13.0 ± 0.00
(13.0) [0.0]
19.3 ± 3.21
(19.2) [16.6]
24.3 ± 7.77
(23.6) [31.9]
1.00
1.07

20 mg/kg (n=3)
302,000 ± 107,000
(291,000) [35.6]
357,000 ± 185,000
(329,000) [51.7]
350,000 ± 105,000
(341,000) [29.9]
3.83 (3.75−4.00)
3.92 (3.75−4.00)
3.92 (3.75−4.50)
1,520,000 ± 806,000
(1,400,000) [53.0]
1,660,000 ± 1,030,000
(1,470,000) [62.2]
1,560,000 ± 637,000
(1,490,000) [40.7]
1,520,000 ± 806,000
(1,400,000) [53.0]
1,660,000 ± 1,030,000
(1,470,000) [62.2]
1,560,000 ± 637,000
(1,490,000) [40.7]
0.778 ± 0.217
(0.757) [27.9]
1.34 ± 0.753
(1.20) [56.0]
1.03 ± 0.242
(1.01) [23.5]
989 ± 278
(959) [28.1]
954 ± 335
(909) [35.1]
917 ± 214
(901) [23.4]
2900 ± 439
(2870) [15.2]
2910 ± 661
(2860) [22.7]
2930 ± 233
(2930) [7.9]
19.75 (13.92−20.00)
19.75 (15.25−23.92)
20.50 (15.92−23.75)
23.7 ± 8.08
(22.8) [34.2]
36.0 ± 4.58
(35.8) [12.7]
45.3 ± 15.0
(43.4) [33.1]
1.09
1.03

AUC, area under the plasma concentration–time curve extrapolated to infinity; AUClast , area under the plasma concentration–time curve calculated using the
trapezoidal method from last time point attributable to the administered drug; CL, apparent total body clearance from the plasma; Clast , last concentration
above the limit of quantitation considered to be due to administered drug effect; Cmax , maximum plasma concentration observed; CV, coefficient of variation;
SD, standard deviation; t½z , terminal half-life; tlast , time corresponding to the last time point attributable to the administered drug and above the limit of
quantitation, Clast ; tmax , time to reach Cmax ; Vss , mean steady-state volume of distribution.
∗ Week 1, 1st infusion; Week 13, 7th infusion; Week 25, 13th infusion.
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Table 4
Avalglucosidase alfa pharmacokinetic parameters for Pompe disease patients previously treated with alglucosidase alfa for ≥9 months (Switch Group).
Parameter

Cmax , ng/mL, mean ± SD
(geometric mean) [CV%]

Week∗

1
13
25

tmax , h, median (min−max)
AUClast , ng·h/mL, mean ± SD
(geometric mean) [CV%]

1
13
25
1
13
25

AUC, ng·h/mL, mean ± SD
(geometric mean) [CV%]

1
13
25

t½z , h, mean ± SD
(geometric mean) [CV%]

1
13
25

CL, mL/h, mean ± SD
(geometric mean) [CV%]

1
13
25

Vss , mL, mean ± SD
(geometric mean) [CV%]

1

25
tlast , h, median (min−max)
Clast , ng/mL, mean ± SD
(geometric mean) [CV%]

1
13
25
1
13
25

Accumulation ratio (AUC)

13
25

Avalglucosidase alfa
5 mg/kg (n=4)

10 mg/kg (n=4)

77,400 ± 22,400
(74,800) [29.0]
103,000 ± 42,800
(96,300) [41.4]
97,100 ± 36,400
(90,900) [37.6]
1.84 (1.38−2.60)
1.64 (1.52−2.58)
1.97 (1.50−2.62)
246,000 ± 81,500
(236,000) [33.1]
296,000 ± 84,200
(288,000) [28.4]
306,000 ± 79,900
(298,000) [26.1]
246,000 ± 81,500
(236,000) [33.1]
296,000 ± 84,200
(288,000) [28.4]
306,000 ± 79,900
(298,000) [26.1]
0.668 ± 0.299
(0.628) [44.8]
0.656 ± 0.253
(0.626) [38.5]
1.53 ± 0.520
(1.47) [33.8]
1570 ± 362
(1530) [23.1]
1290 ± 319
(1260) [24.7]
1240 ± 342
(1210) [27.7]
3710 ± 1520
(3490) [40.9]
2830 ± 762
(2750) [26.9]
2880 ± 704
(2820) [24.4]
9.68 (9.60−17.67)
9.62 (9.60−18.67)
20.04 (13.58−25.75)
19.0 ± 5.48
(18.5) [28.8]
19.0 ± 4.08
(18.7) [21.5]
23.8 ± 12.7
(21.1) [53.6]
1.20
1.24

168,000 ± 36,800
(165,000) [21.9]
171,000 ± 45,100
(166,000) [26.4]
164,000 ± 19,100
(163,000) [11.6]
2.27 (1.75−2.43)
2.44 (2.28−2.72)
2.51 (2.25−3.35)
631,000 ± 118,000
(622,000) [18.7]
668,000 ± 186,000
(646,000) [27.9]
642,000 ± 46,900
(641,000) [7.3]
631,000 ± 118,000
(622,000) [18.7]
668,000 ± 186,000
(646,000) [27.9]
642,000 ± 46,900
(641,000) [7.3]
1.03 ± 0.628
(0.920) [61.1]
0.838 ± 0.214
(0.821) [25.5]
0.712 ± 0.103
(0.706) [14.5]
1280 ± 246
(1270) [19.2]
1280 ± 448
(1230) [35.1]
1230 ± 56.3
(1230) [4.6]
3210 ± 839
(3140) [26.1]
3280 ± 1080
(3170) [32.9]
3060 ± 114
(3060) [3.7]
14.47 (14.33−26.50)
14.48 (14.28−18.67)
14.34 (12.70−14.35)
15.8 ± 1.71
(15.7) [10.8]
19.3 ± 4.57
(18.8) [23.8]
22.5 ± 10.5
(21.0) [46.5]
1.06
1.02

20 mg/kg (n=6, Week 1
and 13; n=5, Week 25)
321,000 ± 125,000
(303,000) [38.9]
327,000 ± 90,200
(317,000) [27.6]
299,000 ± 47,500
(296,000) [15.9]
3.83 (3.68−4.73)
3.86 (3.58−4.23)
3.83 (3.68−5.58)
1,500,000 ± 502,000
(1,430,000) [33.4]
143,0000 ± 529,000
(1,350,000) [37.0]
1,530,000 ± 434,000
(1,480,000) [28.5]
1,500,000 ± 502,000
(1,430,000) [33.4]
1,430,000 ± 529,000
(1,350,000) [37.0]
1,530,000 ± 434,000
(1,480,000) [28.5]
0.876 ± 0.232
(0.852) [26.5]
0.849 ± 0.254
(0.816) [29.9]
1.06 ± 0.435
(1.00) [40.9]
1060 ± 198
(1050) [18.6]
1160 ± 321
(1120) [27.6]
998 ± 204
(982) [20.5]
3310 ± 731
(3250) [22.1]
3510 ± 952
(3390) [27.2]
3290 ± 755
(3210) [23.0]
17.87 (15.75−21.03)
17.95 (11.75−21.83)
16.77 (15.67−21.58)
29.7 ± 19.5
(25.4) [65.7]
34.8 ± 16.8
(32.0) [48.2]
47.8 ± 33.7
(40.3) [70.4]
0.95
1.02

AUC, area under the plasma concentration–time curve extrapolated to infinity, AUClast , area under the plasma concentration–time curve calculated using the
trapezoidal method from last time point attributable to the administered drug; CL, apparent total body clearance from the plasma; Clast , last concentration
above the limit of quantitation considered to be due to administered drug effect; Cmax , maximum plasma concentration observed; CV, coefficient of variation;
SD, standard deviation; t½z , terminal half-life; tlast , time corresponding to the last time point attributable to the administered drug and above the limit of
quantitation, Clast ; tmax , time to reach Cmax ; Vss , mean steady-state volume of distribution.
∗ Week 1, 1st infusion; Week 13, 7th infusion; Week 25, 13th infusion.
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Fig. 4. Mean avalglucosidase alfa plasma concentrations following every-other-week infusions of avalglucosidase alfa (n=3 to 6 per dose level). (a) Week 1,
(b) Week 13, and (c) Week 25. Limit of quantitation (LoQ)=13 ng/mL.
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Fig. 5. Evaluation of intact muscle and fatty replacement by MRI (a) Mercuri score, (b) 3-point Dixon, (c) T2 with B1 , and (d) T2 without B1 .

glycogen content at baseline was 6.0±7.3% in the Naïve
Group and 6.5±7.9% in the Switch Group. For most patients,
quadriceps muscle glycogen levels remained unchanged from
baseline to Week 27 (see Supplementary Fig. S1A and B).
Urinary Hex4 concentrations over time for individual
patients in the Naïve and Switch groups are shown in
Supplementary Fig. S2A and B, respectively. At Week 13,
across both groups, mean±SD % changes from baseline in
urinary Hex4 concentrations decreased at all avalglucosidase
alfa dose levels, except in the 5 mg/kg Switch Group
(4.3±8.8%). At Week 25, the % changes from baseline were:
Naïve Group: –30.3±18.6%, –36.0±6.9%, and –13.2±40.6%
for the 5, 10, and 20 mg/kg avalglucosidase alfa groups,
respectively, and Switch Group: –7.5±38.8%, –12.0±29.7%,
and –20.5±27.8% for the 5, 10, and 20 mg/kg avalglucosidase
alfa groups, respectively.
Evaluation of intact muscle and fatty replacement in the
upper leg (thigh) and lower leg with Mercuri scores, 3point Dixon, and T2 MRI with and without B1 mapping,

demonstrated minimal changes throughout the study for
both Naïve and Switch Group patients (Fig. 5A–D). Similar
findings were observed across both groups. In the Naïve
group, some changes from baseline in the upper leg 3-point
Dixon parameter at Week 27 corresponded to nominal pvalues of <0.05 for the 5 and 10 mg/kg, and overall groups
(19.4% change [95% CI: 1.0, 37.9], p=0.0438; 20.6% change
[95% CI: 14.4, 26.9], p=0.0153; and 15.9% change [95%
CI: 6.6, 25.2], p=0.0050, respectively). In the Switch Group
at Week 27, some changes from baseline corresponded to
nominal p-values of <0.05; these were the for the upper
and lower legs T2 without B1 for the 5 mg/kg group (12.3%
[95% CI: 5.0, 19.6], p=0.0185 and 5.0% [95% CI: 0.5, 9.5],
p=0.0413, respectively) and for the lower leg T2 with B1 for
the overall group (2.5% [95% CI 0.1, 4.8], p=0.0451). For
both the Naïve and Switch Groups, all other % changes from
baseline at Week 27 for the four pharmacodynamics response
parameters in any treatment group or overall did not reach
nominal significance.
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Fig. 6. Upright % predicted forced vital capacity (FVC), maximal expiratory pressure (MEP), and minimal inspiratory pressure (MIP) for individual patients
and treatment means.

3.7. Exploratory efficacy
3.7.1. Pulmonary function
Upright % predicted FVC, MEP, and MIP for individual
patients along with treatment means at baseline, and Weeks 13
and 25 for the Naïve and Switch Groups are shown in Fig.
6 (see Supplementary Table S4 for the mean±SD, median,
minimum, and maximum FVC, MEP, and MIP values at

each time point, along with mean % change from baseline
at Week 25 for each treatment). In both groups, pulmonary
function generally improved or was stable at Week 25 relative
to baseline.
3.7.2. 6MWT
The % predicted 6MWT distances for individual patients
and treatment means are shown in Fig. 7 (Supplementary
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Fig. 7. 6-min walk test (6MWT) % predicted, (a) Naïve Group and (b) Switch Group.

Table S5 shows a summary of mean±SD, median, minimum,
and maximum % predicted 6MWT distances at baseline and
Week 25, along with changes from baseline at Week 25 for
both groups by dose level). At baseline, during the 6MWT
patients in the Naïve Group walked a mean±SD total distance
of 449±118 (range 208–593) m and those in the Switch
Group walked total distance of 440±141 (range 201–657)
m. In the Naïve Group, mean±SD changes from baseline
in 6MWT distances were 12.0±21.0 m, –15.3±15.5 m, and
24.3±23.0 m for the 5, 10, and 20 mg/kg groups, respectively,
and for the Switch Group they were –4.0±30.5 m, 4.3±8.1 m,
and –6.2±64.3 m, respectively.
3.7.3. GSGC test
For the Naïve and Switch Groups, mean changes from
baseline at Week 25 for functional ability GSGC score
remained unchanged relative to baseline at all doses, with
overall means of –0.8 for the Naïve Group and 0.2 for the
Switch Group.
The GSGC combines timed tests for walking 10 m,
climbing four stairs, standing from sitting on the floor and
standing from sitting on a chair. Although, the total score
for these four tests did not change over the course of
the study, test results for selected subtests showed mean
decreases in both Naïve and Switch Group patients. The
mean±SD changes from baseline for times to walk 10 m,
climb four stairs, stand from sitting on the floor, and stand
from sitting on a chair at Week 25 for the overall Naïve
Group were –0.6±1.01 s, –1.1±2.21 s, –3.0±6.72 s, and –
0.2±0.86 s, respectively, and for the overall Switch Group
were –0.4±2.73 s, –0.5±2.83 s, 1.7±3.12 s, and –0.1±0.72 s,
respectively.
3.7.3. GMFM-88 test
GMFM-88-DE scores for individual patients and treatment
means are shown in Fig. 8A and B, for the Naïve and

Switch Groups, respectively. For both groups, mean scores
for Dimensions D (standing) and E (walking, running,
and jumping), and the combined GMFM-88-DE functional
strength total assessments remained unchanged relative to
baseline in all treatment groups. The % mean±SD change
from baseline for GMFM-88-DE score at Week 25 for the
overall Naïve Group was 3.0±5.9% and for the overall Switch
Group was 2.2±9.0%.
3.7.4. QMFT
QMFT scores for individual patients and treatment means
are shown in Fig. 8C and D, for the Naïve and Switch Groups,
respectively. In the Naïve Group, the mean±SD QMFT scores
changed relative to baseline at Week 25 in the 5, 10, and
20 mg/kg groups by 0.7±4.9, 1.7±2.3, and 3.0±2.7 points,
respectively, whilst in the Switch Group they changed by
–1.5±2.7, 3.0±1.6, and 1.2±1.9 points, respectively.
3.7.5. HHD test
Lower body HHD scores for individual patients and
treatment means are shown in Fig. 8E and F, for the Naïve and
Switch Groups, respectively. In the Naïve Group, lower body
HHD assessments changed at Week 25 relative to baseline by
a mean±SD of 11.6±4.7%, 21.4±10.3%, and 14.2±15.9%
in the 5, 10, and 20 mg/kg groups, respectively, whilst for
the upper body assessments they changed by 8.2±25.9%,
19.0±7.5%, and –9.9±16.9%, respectively. In the Switch
Group, lower body HHD assessments changed at Week 25
relative to baseline by –0.5±13.1%, 14.3±27.3%, and –
14.5±42.2% in the 5, 10, and 20 mg/kg groups, respectively,
whilst for the upper body assessments they changed by
–8.1±24.5%, 10.8±17.8%, and –15.3±27.7%, respectively.
3.7.6. PedsQL
For both groups, mean scores for cognitive fatigue, general
fatigue, and sleep/rest fatigue were mostly unchanged relative
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Fig. 8. Gross Motor Function Measure-88 for Dimensions D and E (GMFM-88-DE), Quick Motor Function Test (QMFT), and Hand-Held Dynamometry
(HHD) sum of lower body for the Naïve Group (a, c, and e, respectively) and the Switch Group (b, d, and f, respectively).

to baseline. However, in the Naïve Group, there was a
mean±SD increase in cognitive fatigue from baseline at
Week 25 in the 5 mg/kg group (–13.9±6.4) and a decrease
in cognitive fatigue and general fatigue (11.1±9.6 and
8.3±7.2, respectively) in the 20 mg/kg group. For the Switch
Group, the two greatest increases in fatigue from baseline
at Week 25 were for general fatigue in the 5 mg/kg group (–
12.5±4.8) and for sleep/rest fatigue, also in the 5 mg/kg group
(–6.2±4.2).

4. Discussion
In this open-label, ascending-dose study, avalglucosidase
alfa was generally safe and well-tolerated at doses of 5,
10, and 20 mg/kg in adult patients with Pompe disease
who were either treatment-naïve or had previously been
treated with alglucosidase alfa for ≥9 months. No deaths
or life-threatening SAEs were reported. Three treatmentemergent SAEs were reported by 2 patients. One Naïve Group
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(5 mg/kg) patient reported two SAEs of respiratory distress
and chest discomfort, both were considered study-drug related
and led to study withdrawal. The other patient who reported
a SAE was in the Switch Group (5 mg/kg) and experienced
gastrointestinal hemorrhage, which was not considered study
drug-related and did not lead to treatment discontinuation or
study withdrawal. For both groups, the majority of TEAEs
were mild across all dose levels. Across both groups, 25 IARs
were reported in 8 (33%) patients.
Anti-avalglucosidase alfa antibodies were characterized
because rhGAA studies suggest that antibodies to exogenous
GAA may affect IARs [48] and/or efficacy in some LOPD
patients [49]. Seroconversion for anti-avalglucosidase alfa
antibodies was detected in the majority (90%) of Naïve
Group patients and in 2 of 9 (22%) Switch Group
patients, who had no anti-avalglucosidase alfa antibodies
at baseline. Highest peak titers were 25,600 (1 Naïve
Group patient) and 12,800 (1 Switch Group patient); the
patient in the Naïve group improved on pulmonary and
motor function testing and the patient in the Switch group
improved on pulmonary function testing and declined on
motor function testing. Titers for the remaining Naïve
Group seroconverters remained ≤3200 and for the remaining
Switch Group seroconverters remained ≤1600. No patients
tested positive for enzyme activity inhibition, and only
1 patient, who was in the Naïve Group, tested positive
for enzyme uptake inhibition. We note the presence
of antibodies to avalglucosidase alfa at baseline in the Switch
group, which may represent cross-reactivity with common
epitopes from recombinant human GAA. Complement
appeared to mediate IARs in 1 patient per group, although
only 2 Naïve Group and 1 Switch Group patients were tested.
Avalglucosidase alfa plasma concentrations appeared to
decline monoexponentially following the end of the infusion,
with a mean t½z of ∼1.0 h for both groups; consistent
with avalglucosidase alfa non-clinical data, this was relatively
shorter than observed for alglucosidase alfa (2.3 h) [25].
Avalglucosidase alfa pharmacokinetics appeared generally
similar between groups and avalglucosidase alfa exposure
increased with dose. The pharmacokinetic parameters
appeared similar at Weeks 1, 13, and 25, indicating no
apparent effect of every-other-week dosing on avalglucosidase
alfa pharmacokinetics.
Baseline quadriceps muscle biopsy glycogen levels were
generally low (∼6% of tissue area) in both groups and
remained mostly unchanged throughout the study. In addition,
glycogen content is generally low in adults with Pompe
disease and there is limited longitudinal information regarding
glycogen clearance from muscle with enzyme replacement
therapy. In the Exploratory Muscle Biopsy Assessment Study
(EMBASSY) of alglucosidase alfa in LOPD [21], quadriceps
biopsy glycogen was found both in lysosomes and cytoplasm
at baseline (mean 5.3%; range 1.0–14.2%); after 24 weeks’
therapy, lysosomal glycogen decreased in 10 patients and
increased in 3 patients. Statistically significant changes were
noted in 6 patients (4 had decreased glycogen and 2 increased
glycogen), while cytoplasmic glycogen remained, and the
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total area of glycogen showed small reductions from baseline.
Similarly, a study by Ripolone et al. [50] showed quadriceps
biopsy improvements (e.g., fewer small Periodic Acid–
Schiff (PAS)-positive glycogen accumulations and reduced
severity of vacuolation, using different techniques than in
EMBASSY or our study) in 15 of 18 LOPD patients after
≥6 months of alglucosidase alfa. Thus, biopsy results from
our current avalglucosidase alfa study appear to be similar to
alglucosidase alfa studies in LOPD.
Across both groups, urinary Hex4 levels decreased at all
avalglucosidase alfa doses (indicating reduction of glycogen
burden), except for 5 mg/kg at Week 13 for the Switch
Group. The trend for reduction was most pronounced in the
Naïve group, similar to trends described in IOPD patients at
initiation of enzyme replacement therapy [51]. There was no
clear relationship to dose level. Of note, Hex4 levels in LOPD
prior to therapy are often not as high as those in IOPD [52],
so that post-treatment trends may be less clear-cut in LOPD.
Muscle MRI at baseline indicated relatively mildly affected
patients in both groups, which remained largely stable with
little change throughout the 24-week treatment period. These
results were similar to the EMBASSY study of alglucosidase
alfa in LOPD [21], in which patients began with a mild degree
of involvement and MRI parameters did not change materially
during 6 months of treatment.
In both groups, pulmonary function generally improved or
was stable at Week 25 relative to baseline in most patients.
The evaluation of FVC % predicted is widely used as a
pulmonary function endpoint in Pompe disease [53] and other
neuromuscular diseases. In chronic respiratory diseases, FVC
change over time is a valid measurement [54]. Repeated FVC
% predicted measurement in untreated LOPD has revealed
annual changes of −1.0% to −4.6% upright and 1.3% to
−5.5% supine [54]. MIP and MEP have been evaluated in
only four published papers on Pompe disease [55–58].
While efficacy assessments were purely exploratory, for
both groups, patients remained stable or demonstrated
improvements via several functional assessments. 6MWT
distances were generally stable or tended to increase with
avalglucosidase alfa, without a clear relationship to patient
group or dose level. For both groups, GSGC and GMFM-88
assessments showed minimal changes, whereas improvements
were observed in the QMFT and HHD evaluations. Decreases
in cognitive and general fatigue were reported at 20 mg/kg
avalglucosidase alfa by Naïve Group patients. Fatigue is
salient in patients’ experience of LOPD, with 2 out
of 3 International Pompe Association survey respondents
identifying it as among the three most disabling symptoms
[59]. Decreased fatigue on avalglucosidase alfa therapy in
naïve patients in our study parallels previous experience of
reduced fatigue in alglucosidase alfa recipients [59,60].
The focus of this phase 1 study was safety,
pharmacokinetic, and pharmacodynamic characteristics
of avalglucosidase alfa in a small cohort of LOPD patients.
Exploratory efficacy parameters demonstrated, in general,
that pulmonary function remained stable or improved,
as did functional capacity. The LOTS [28,29], a study
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of alglucosidase alfa in children and adults with LOPD,
demonstrated improvement in pulmonary function and
distance walked after 78 weeks of therapy. It is therefore
reassuring that functional and respiratory decline was
not observed during this short period of treatment with
avalglucosidase alfa.
Our study had some limitations. Firstly, a primary efficacy
period of only 24 weeks precluded assessment of long-term
treatment effects. Secondly, since the study cohort was small,
with only 3–6 patients per dose group, it is difficult to draw
firm conclusions from the data regarding efficacy. Finally,
the design of the study does not allow comparison with
previous safety or immunogenicity data from alglucosidase
alfa studies that were placebo-controlled or open-label and not
dose-escalating. The currently recruiting head-to-head study,
COMET (NCT02782741), will directly compare the efficacy
and safety of avalglucosidase alfa with alglucosidase alfa in
LOPD patients not previously treated for Pompe disease with
enzyme replacement therapy.
5. Conclusions
Avalglucosidase alfa had a well-tolerated safety profile in
LOPD patients, either naïve to alglucosidase alfa therapy or
who had previously received alglucosidase alfa therapy for
≥9 months. Whilst the efficacy assessments were exploratory,
the results of this study support further development of
avalglucosidase alfa.
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